Health deep tech startup Mesh Bio received undisclosed funding from East Ventures

Mesh Bio, a Singapore-based health deep tech business, reported that it has received funding from East Ventures, a venture capital company with a focus on Southeast Asia, for an undisclosed sum.

According to a statement from Mesh Bio, the money will be used to expand its services throughout Southeast Asia, particularly in Indonesia, Malaysia, and the Philippines, and to further develop digital twin technologies for the management of chronic diseases.

“Given the increasing aging population worldwide, Mesh Bio has consistently prioritized the development of innovative solutions to alleviate healthcare challenges associated with chronic diseases,

“We are glad to receive the support from East Ventures, and we are confident that this funding will serve as a strong foundation in our vision to confront the rising burden of chronic diseases across the regions,” said Dr. Andrew Wu, Co-Founder and Chief Executive Officer of Mesh Bio.

Mesh Bio is a digital health startup that was established in 2018 by Andrew Wu (Co-Founder and Chief Executive Officer) and Arsen Batagov (Co-Founder and Chief Technology Officer) to address the growing clinical burden of metabolic diseases around the world as a result of aging populations and care delivery issues.

The company creates automation and analytics tools for clinical decision assistance in the treatment of chronic diseases including cardiovascular disease.

By enabling data-driven care delivery, these systems enhance patient involvement and health outcomes.

According to Mesh Bio, the company has the goal to provide state-of-the-art digital solutions to tackle issues with patient management and the regional rise in chronic diseases.

Noncommunicable diseases (NCDs) or chronic diseases, like cardiovascular disease and diabetes, place a significant and expanding burden on health and development in the Southeast Asia area, claims the statement.

It was stated that 9 million people, or 62 percent of deaths in the region, were attributable to NCDs.

According to the article, the rise in chronic diseases makes patient treatment difficult and complex.

Additionally, it was stated that the shortage of physicians, particularly specialists, made the problem worse because general practitioners, who lack specialized training in endocrinology, are obliged to handle these difficult patient cases.